AI Research
Revolution Medicines Partners With Iambic in $25M AI Drug Discovery Deal

Revolution Medicines (Nasdaq: RVMD) and Iambic Therapeutics have announced a multi-year technology and research collaboration to develop novel drug candidates using Iambic’s AI-driven discovery platform. The partnership centers on training custom versions of Iambic’s NeuralPLexer model using Revolution Medicines’ proprietary data and structures.
As part of the agreement, Iambic will receive up to $25 million in upfront and near-term performance-based milestone payments, plus ongoing R&D reimbursements. Both companies will have access to the improved models and retain rights to exclusive targets for independent pursuit.
Revolution Medicines (Nasdaq: RVMD) e Iambic Therapeutics hanno annunciato una collaborazione tecnologica e di ricerca pluriennale per sviluppare nuovi candidati farmaci utilizzando la piattaforma di scoperta basata su intelligenza artificiale di Iambic. La partnership si concentra sull’addestramento di versioni personalizzate del modello NeuralPLexer di Iambic, impiegando i dati e le strutture proprietarie di Revolution Medicines.
Secondo l’accordo, Iambic riceverà fino a 25 milioni di dollari in pagamenti anticipati e milestone basati sulle performance a breve termine, oltre a rimborsi continui per la ricerca e sviluppo. Entrambe le aziende avranno accesso ai modelli migliorati e manterranno i diritti su obiettivi esclusivi per un’eventuale sviluppo indipendente.
Revolution Medicines (Nasdaq: RVMD) y Iambic Therapeutics han anunciado una colaboración tecnológica e investigadora de varios años para desarrollar nuevos candidatos a fármacos utilizando la plataforma de descubrimiento impulsada por IA de Iambic. La asociación se centra en entrenar versiones personalizadas del modelo NeuralPLexer de Iambic usando los datos y estructuras propietarias de Revolution Medicines.
Como parte del acuerdo, Iambic recibirá hasta 25 millones de dólares en pagos iniciales y hitos basados en el rendimiento a corto plazo, además de reembolsos continuos para I+D. Ambas compañías tendrán acceso a los modelos mejorados y conservarán los derechos sobre objetivos exclusivos para su desarrollo independiente.
Revolution Medicines (나스닥: RVMD)와 Iambic Therapeutics는 Iambic의 AI 기반 신약 발견 플랫폼을 활용하여 새로운 약물 후보를 개발하기 위한 다년간의 기술 및 연구 협력을 발표했습니다. 이 파트너십은 Revolution Medicines의 독점 데이터와 구조를 사용하여 Iambic의 NeuralPLexer 모델 맞춤 버전을 학습하는 데 중점을 둡니다.
계약의 일환으로 Iambic은 최대 2,500만 달러의 선불 및 단기 성과 기반 마일스톤 지급금과 지속적인 연구개발 비용 환급을 받게 됩니다. 양사는 개선된 모델에 접근할 수 있으며 독립적으로 추진할 수 있는 독점 대상에 대한 권리를 유지합니다.
Revolution Medicines (Nasdaq : RVMD) et Iambic Therapeutics ont annoncé une collaboration technologique et de recherche pluriannuelle visant à développer de nouveaux candidats médicaments en utilisant la plateforme de découverte pilotée par l’IA d’Iambic. Le partenariat porte sur la formation de versions personnalisées du modèle NeuralPLexer d’Iambic, en utilisant les données et structures propriétaires de Revolution Medicines.
Dans le cadre de cet accord, Iambic recevra jusqu’à 25 millions de dollars en paiements initiaux et en jalons basés sur la performance à court terme, ainsi que des remboursements continus pour la R&D. Les deux entreprises auront accès aux modèles améliorés et conserveront les droits sur des cibles exclusives pour un développement indépendant.
Revolution Medicines (Nasdaq: RVMD) und Iambic Therapeutics haben eine mehrjährige Technologie- und Forschungspartnerschaft angekündigt, um neuartige Arzneimittelkandidaten mithilfe der KI-gestützten Entdeckungsplattform von Iambic zu entwickeln. Der Schwerpunkt der Zusammenarbeit liegt auf dem Training maßgeschneiderter Versionen des NeuralPLexer-Modells von Iambic unter Verwendung der proprietären Daten und Strukturen von Revolution Medicines.
Im Rahmen der Vereinbarung erhält Iambic bis zu 25 Millionen US-Dollar als Vorauszahlung und leistungsabhängige Meilensteinzahlungen in naher Zukunft sowie fortlaufende F&E-Erstattungen. Beide Unternehmen erhalten Zugang zu den verbesserten Modellen und behalten die Rechte an exklusiven Zielen zur eigenständigen Verfolgung.
Negative
- Significant upfront and milestone payment commitments of up to $25 million
- Success depends on unproven AI-driven drug discovery approach
- Shared rights to improved models may limit competitive advantages
Insights
Revolution Medicines’ AI partnership with Iambic could accelerate oncology drug discovery while limiting financial exposure.
This collaboration represents a strategic technology integration that could significantly enhance Revolution Medicines’ drug discovery capabilities in their RAS-addicted cancer portfolio. The partnership grants RVMD access to Iambic’s NeuralPLexer and PropANE AI models, which specialize in protein-ligand structure prediction and drug property optimization, respectively.
The financial structure is favorable for Revolution Medicines, with a capped commitment of
The deal structure is particularly noteworthy as it allows both companies to retain rights to exclusive targets, creating potential for multiple shots on goal while allowing Revolution Medicines to maintain control over key assets. By training custom AI models on their proprietary data, RVMD is essentially building a technological moat around their existing intellectual property while potentially extracting more value from it.
For a late-stage clinical company like Revolution Medicines, this AI integration could help expand their pipeline while their lead RAS-targeting programs advance through clinical development. The multi-year timeframe suggests this is a long-term strategic move rather than a quick fix, indicating management’s forward-thinking approach to leveraging AI for competitive advantage in the increasingly crowded precision oncology space.
- Custom-built model will be trained using Revolution Medicines’ proprietary data to discover novel drug candidates
- Iambic to receive up to
$25 million through a combination of upfront and expected near-term performance-based milestone payments for services related to Revolution Medicines’ access to Iambic’s industry-leading NeuralPLexer model for protein structure prediction
REDWOOD CITY, Calif. and SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, and Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a technology and research collaboration to pursue novel drug candidates using Iambic’s leading AI models.
In this multi-year agreement, Iambic will use structures and molecular libraries provided by Revolution Medicines to train bespoke versions of NeuralPLexer, Iambic’s industry-leading model for protein-ligand structure prediction. Revolution Medicines will also have access to Iambic’s PropANE model, a pre-trained graph neural network deployed across dozens of drug properties for lead selection and optimization.
“We are impressed with the Iambic team and the potential of their platform to enable the discovery of novel compounds on behalf of Revolution Medicines’ portfolio,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. “The capabilities of Iambic’s AI-driven discovery platform, partnered with our unique collection of proprietary data, present an opportunity to rapidly explore oncology targets known to be challenging to address through conventional drug discovery approaches.”
Iambic will build custom versions of NeuralPLexer and other technologies trained on Revolution Medicines’ proprietary data to inform drug discovery against novel drug targets. Both companies will have access to the improved models, and each company retains rights to a limited number of exclusive targets as well as the ability to designate additional exclusive targets to pursue independently.
“We are thrilled to work with a visionary company like Revolution Medicines on what we believe is a novel biopharma collaboration,” said Tom Miller, Ph.D., chief executive officer and co-founder of Iambic. “This collaboration enables us to expand the impact of our AI technologies as we endeavor to build industry-leading models and medicines. We have applied approaches that underly this collaboration internally and are excited to offer these approaches externally to great partners like Revolution Medicines.”
Under the agreement, Iambic will receive up to
About Iambic’s AI-Driven Discovery Platform
The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as NeuralPLexer for best-in-class prediction of protein and protein-ligand structures. The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence.
About Iambic Therapeutics
Founded in 2020 and headquartered in San Diego, California, Iambic is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has demonstrated delivery of high-quality, differentiated therapeutics to the clinical stage with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai
Iambic Contact:
media@iambic.ai
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
Revolution Medicines Forward Looking Statements
This press release contains forward-looking statements regarding Revolution Medicines within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding the ability of the company to explore oncology targets and the pace of this exploration; and the aims and plans of the collaboration with Iambic Therapeutics. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ current stage of development, the process of designing and conducting preclinical and clinical trials, risks that the results of prior clinical trials may not be predictive of future clinical trials, clinical efficacy, or other future results, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company’s business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on May 7, 2025, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
FAQ
What is the value of the collaboration between Revolution Medicines (RVMD) and Iambic Therapeutics?
The collaboration is valued at up to $25 million, including upfront payments, near-term performance-based milestones, and ongoing R&D reimbursements.
What AI technologies will Revolution Medicines (RVMD) gain access to through this partnership?
Revolution Medicines will gain access to Iambic’s NeuralPLexer model for protein-ligand structure prediction and PropANE model for lead selection and optimization.
How will the Revolution Medicines and Iambic collaboration work?
Iambic will use Revolution Medicines’ structures and molecular libraries to train custom versions of their AI models, with both companies having access to the improved models and rights to exclusive targets.
What is the main goal of the RVMD-Iambic partnership?
The partnership aims to discover novel drug candidates for RAS-addicted cancers using Iambic’s AI-driven discovery platform, particularly focusing on oncology targets that are challenging to address through conventional approaches.
Who retains the rights to the drug discoveries from the RVMD-Iambic collaboration?
Both companies will retain rights to a limited number of exclusive targets and can designate additional exclusive targets to pursue independently.
AI Research
Proactive, Autonomous, Seamless Customer Support

SAP Business AI can boost productivity with technology that aligns with the AI strategies of our customers—ranging from building effective agents to managing intelligent systems.
Among the many announcements at SAP Sapphire in 2025, the company unveiled new innovations, partnerships, and integrations that can deliver real-time, proactive assistance. For example, SAP’s AI copilot Joule is now available to users across SAP and non-SAP systems. SAP also expanded its agentic AI footprint across SAP Business Suite by introducing Joule Agents for multiple use cases and an evolving AI Foundation as the AI operating system designed to simplify development, enabling developers to build, deploy, and scale solutions with ease.
The impact of AI on the delivery of customer support at SAP
As announced in Q2 this year, SAP’s simplified, tiered, services-and-support engagement model will be generally available in early 2026. Here, SAP’s customer support is a centerpiece of the Foundational Success Plan, delivered via the proven SAP Enterprise Support offering included in every SAP cloud solution subscription. The Foundational Success Plan can support in-house teams by helping to onboard and run solutions, keep business continuity, and drive ongoing value. It includes customer self-service options, application lifecycle management solutions centered around SAP Cloud ALM, and preventative mission-critical support. With the plan, SAP turns on Joule for a customer’s business and supports the team ramp-up with learning journeys for SAP Business AI.
When it comes to customer support in general, agentic AI can redefine the support process by moving beyond scripted responses and basic automation. It can assess situations, make decisions, and take action—often before the customer even knows there’s an issue. SAP’s customer support harnesses agentic AI to help deliver smarter assistance, faster resolutions, and a stronger human–tech partnership.
We focus on elevating support experiences for customers and improving support delivery for engineers by employing a combination of agents and assistants. For example, we use autoresponders and smart log analyzers to help process issues, while configuration advisors, language services, and proactive notifiers can guide customers toward self-service solutions. At the same time, our support engineers rely on co-pilots to help summarize cases, recommend solutions, escalate using intelligence, assist with communications, and create a continuous feedback loop for learning. For strategic customer support, we use tools like feedback collectors to help capture customer insights and channel recommenders to help ensure that every interaction is handled in the right channel. Together, these innovations can redefine support as faster, smarter, and more human.
The impact for customers
When it comes to SAP Business AI, we build trust and create customer confidence by being relevant, reliable, and responsible. Unlike traditional AI that only suggests answers, agentic AI can reason, decide, and take action. For customers to feel confident, they expect accuracy, reliability, and transparency from the system.
As we support and guide our customers, we recognize that while agentic AI is a game-changer, it is not a magic pill. Coupled with ethical and responsible AI, real impact comes from SAP’s business expertise and a deep understanding of what our customers truly need. When knowledge is combined with AI to infuse autonomy and interoperability in our agents, we can unlock the ability to simplify processes, remove friction, and deliver experiences that feel effortless.
AI technology amplifies human insight and delivers delightful user experiences, but when it comes to business AI, it is our domain expertise that fuels SAP Business AI into a tool for creating genuinely easy, productive, and meaningful experiences for our customers.
Stefan Steinle is executive vice president and head of Customer Support & Cloud Lifecycle Management at SAP.
AI Research
How AI-powered ZTNA will protect the hybrid future

What I’m seeing in zero-trust deployments
The real story isn’t in the survey data — it’s in the conversations I’m having with enterprise security architects trying to implement zero trust strategies. Last month, I worked with a financial services company that had spent eighteen months evaluating ZTNA solutions. They’d built requirements documents, conducted vendor demos and mapped their application inventory. But when it came time to deploy, they hit a wall.
The problem wasn’t technology. Gartner’s Magic Quadrant shows vendors like Palo Alto Networks, Netskope and Zscaler have mature platforms. The problem was that implementing these solutions required untangling years of VPN configurations, documenting legacy application dependencies and coordinating with stretched application teams.
What struck me was hearing their CISO say, “We bought this ZTNA platform for intelligent, automated access control. Instead, we’re spending more time on manual policy creation than with our old VPN.” That’s when I realized we’re dealing with a deeper issue than technology selection.
AI Research
The impact of artificial intelligence on the food industry

The integration of artificial intelligence (AI) into the food industry is revolutionizing the way food is produced, processed, distributed, and consumed. AI-driven solutions offer unprecedented opportunities for improving efficiency, ensuring safety, reducing waste, and enhancing sustainability in this vital sector. This article explores how AI is transforming various facets of the food industry, from farm to table.
AI in agriculture
The food production process begins on the farm, where AI technologies are helping farmers make smarter decisions. Precision agriculture, powered by AI, uses data from sensors, drones, and satellites to monitor crop health, soil conditions, and weather patterns. Machine learning algorithms analyze this data to provide actionable insights, such as when to irrigate, fertilize, or harvest crops. This approach not only boosts yield but also minimizes the use of water, fertilizers, and pesticides, reducing environmental impact.
Robotics is another AI application making waves in agriculture. Autonomous tractors and robotic harvesters equipped with AI can perform labor-intensive tasks with precision, addressing labor shortages and reducing costs. For instance, AI-enabled robots can differentiate between ripe and unripe fruits, ensuring only the best produce is picked.
Enhancing food processing and manufacturing
AI is playing a critical role in food processing and manufacturing by optimizing operations and ensuring quality control. Advanced vision systems powered by AI can inspect food products for defects, contaminants, or inconsistencies at a speed and accuracy unmatched by human workers. This ensures that only safe and high-quality products reach consumers.
Predictive maintenance is another area where AI is proving invaluable. By monitoring machinery and analyzing operational data, AI can predict equipment failures before they occur, minimizing downtime and maintenance costs. This level of foresight is especially important in food manufacturing, where delays can lead to spoilage and significant financial losses.
In addition to improving efficiency, AI-driven automation is enhancing worker safety by taking over hazardous tasks, such as handling hot or sharp equipment. This contributes to creating a safer work environment in food processing plants.
Supply chain optimization
The food supply chain is a complex network that requires precise coordination to ensure timely delivery of perishable goods. AI-powered tools are streamlining supply chain management by improving forecasting, inventory management, and logistics.
Demand forecasting is a key application of AI in this domain. By analyzing historical sales data, market trends, and external factors like weather or holidays, AI systems can accurately predict demand for different food products. This helps retailers and suppliers avoid overstocking or understocking, reducing food waste and increasing profitability.
AI is also revolutionizing logistics through route optimization and real-time tracking. Advanced algorithms can determine the most efficient delivery routes, reducing fuel consumption and ensuring products reach their destinations as quickly as possible. Additionally, AI can monitor the condition of perishable goods during transit, ensuring they remain within safe temperature ranges.
Enhancing food safety and quality
Food safety is a top priority in the industry, and AI is proving to be a powerful ally in this area. Machine learning algorithms can analyze vast amounts of data from production lines, environmental monitoring systems, and lab tests to identify potential risks or contamination sources.
AI-powered tools are also aiding in the rapid detection of pathogens like Salmonella and E. coli. Traditional testing methods can take days, but AI-based systems can deliver results in hours, enabling quicker responses to potential outbreaks. Moreover, blockchain technology combined with AI is enhancing traceability, allowing stakeholders to track the journey of a product from farm to fork. This transparency helps build consumer trust and simplifies recalls in case of contamination.
Reducing food waste
Food waste is a significant global issue, and AI is offering innovative solutions to address this challenge. AI systems can analyze data from supermarkets, restaurants, and households to identify patterns and suggest ways to reduce waste. For instance, AI can recommend optimal stock levels for retailers, ensuring they do not overorder perishable items.
In the hospitality sector, AI-powered tools can monitor inventory and predict demand, helping chefs prepare just the right amount of food. This not only reduces waste but also cuts costs. Additionally, AI is being used to repurpose surplus food by identifying ways to incorporate it into new recipes or distribute it to those in need.
Personalized nutrition and consumer experience
AI is transforming the way consumers interact with food, offering personalized recommendations based on individual preferences, dietary restrictions, and health goals. Apps and wearable devices equipped with AI can analyze user data to suggest meal plans, track nutritional intake, and even offer cooking tips.
Retailers are also using AI to enhance the shopping experience. AI-powered chatbots and virtual assistants can guide customers in selecting products, answer queries, and provide tailored suggestions. Meanwhile, AI-driven shelf management systems ensure that popular items are always in stock, improving customer satisfaction.
Driving sustainability
Sustainability is a pressing concern for the food industry, and AI is helping companies adopt greener practices. By optimizing resource usage, reducing waste, and improving supply chain efficiency, AI is enabling the industry to lower its carbon footprint.
AI is also playing a role in developing alternative proteins, such as plant-based or lab-grown meat. Machine learning models are being used to optimize formulations, improve texture and taste, and scale production. These innovations are contributing to a more sustainable and ethical food system.
Challenges and future prospects
While the benefits of AI in the food industry are immense, challenges remain. High implementation costs, lack of technical expertise, and concerns about data privacy are some of the barriers to widespread adoption. Additionally, there is a need for robust regulations to ensure ethical use of AI and address potential biases in decision-making.
Despite these challenges, the future of AI in the food industry looks promising. As technology continues to evolve, we can expect even more sophisticated applications that further enhance efficiency, sustainability, and consumer satisfaction. Companies that embrace AI today will be well-positioned to lead the industry into a smarter, more sustainable future.
In conclusion, AI is not just a tool but a transformative force reshaping the food industry. By harnessing its potential, stakeholders can address some of the most pressing challenges in food production, safety, and sustainability, ultimately creating a better food system for everyone.
-
Business3 weeks ago
The Guardian view on Trump and the Fed: independence is no substitute for accountability | Editorial
-
Tools & Platforms1 month ago
Building Trust in Military AI Starts with Opening the Black Box – War on the Rocks
-
Ethics & Policy2 months ago
SDAIA Supports Saudi Arabia’s Leadership in Shaping Global AI Ethics, Policy, and Research – وكالة الأنباء السعودية
-
Events & Conferences4 months ago
Journey to 1000 models: Scaling Instagram’s recommendation system
-
Jobs & Careers3 months ago
Mumbai-based Perplexity Alternative Has 60k+ Users Without Funding
-
Podcasts & Talks2 months ago
Happy 4th of July! 🎆 Made with Veo 3 in Gemini
-
Education3 months ago
VEX Robotics launches AI-powered classroom robotics system
-
Education2 months ago
Macron says UK and France have duty to tackle illegal migration ‘with humanity, solidarity and firmness’ – UK politics live | Politics
-
Podcasts & Talks2 months ago
OpenAI 🤝 @teamganassi
-
Funding & Business3 months ago
Kayak and Expedia race to build AI travel agents that turn social posts into itineraries